tbuckley/cabot-search huggingface dataset:
Restatement of the Position of Meigs on the Behavior of Muscle
Authors: Martin H. Fischer
Journal: JAMA (1913)

What a Local Society Can DoTo the Editor:\p=m-\Oneof our local papers recently carried a large advertisement of "English Hemorrhoidal Remedy," con- taining what purported to be a signed statement from forty local druggists, stating that they were much impressed with the value of this remedy, and unreservedly endorsed it.Our local medical society sent each one of these druggists a letter, asking them to let us know on what they had based this strong endorsement.They scrambled all over each other to send replies disclaiming any such endorsement, and sent back to the exploiters their stocks of the nostrum, which they had held on consignment.One establishment replied naively that it never had approved of this method of advertising,and, as the goods had not sold well, it had sent them back.Our action will materially decrease that kind of advertising in the future, and was well worth the trouble it cost.It is reported as a tip to other local medical societies.In return, perhaps you or somi.e else can tell u-if there
Abstract 3216: Using protein microarray technology to develop mono-specific anti-ERCC1 mAbs for anatomic pathology applications.
Authors: Donghui Ma, Youmin Shu, Kehu Yuan, Wei-Wu He
Journal: Cancer Research (2013)

Abstract Antibody with cross-reactivity can create unexpected side effects or false diagnostic reports if used for clinical purposes. ERCC1 is a predictive biomarker for cisplatin based chemotherapy. High ERCC1 expression is linked to drug resistance to cisplatin-based chemotherapy. 8F1 is one of the most commonly used monoclonal antibodies for evaluating ERCC1 expression levels in lung cancer patient tissue samples. By using high density protein microarray chip, we discovered that 8F1 not only reacts with its authentic target ERCC1, but also cross-reacts with an unrelated nuclear membrane protein, PCYT1A. The cross-reactivity to PCYT1A was further confirmed by other immunoassays, including Western blot, antigen absorption test, and immunohistochemistry (IHC) analyses. In this study, we also discovered that PCYT1A gene expression level is even significantly higher than ERCC1 gene expression level in a certain population of lung cancer patient tissue samples. In summary, 8F1 clone is not suitable for ERCC1 IHC assay due to its cross-reactivity with PCYT1A protein. To develop the best monoclonal antibody for ERCC1 IHC analysis, 18 monoclonal antibodies were generated and 6 of them were screened against our protein microarray chip. Two clones showed high mono-specificity on protein microarray chip test and both worked in IHC application. Citation Format: Donghui Ma, Youmin Shu, Kehu Yuan, Wei-Wu He. Using protein microarray technology to develop mono-specific anti-ERCC1 mAbs for anatomic pathology applications. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3216. doi:10.1158/1538-7445.AM2013-3216
Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study.
Authors: I Kawachi, D Sparrow, P S Vokonas, S T Weiss
Journal: Circulation (1994)

Several studies have suggested an increased risk of fatal coronary heart disease (CHD) among patients with panic disorder, phobic anxiety, and other anxiety disorders. We prospectively examined this association in the Normative Aging Study.An anxiety symptoms scale was constructed out of five items from the Cornell Medical Index, which was administered to the cohort at baseline. During 32 years of follow-up, we observed 402 cases of incident coronary heart disease (137 cases of nonfatal myocardial infarction, 134 cases of angina pectoris, and 131 cases of fatal CHD: made up of 26 cases of sudden cardiac death and 105 cases of nonsudden death). A nested case-control design (involving 1869 control subjects who remained free of diagnosed CHD) was used to assess the association between anxiety and risk of CHD. Compared with men reporting no symptoms of anxiety, men reporting two or more anxiety symptoms had elevated risks of fatal CHD (age-adjusted odds ratio [OR] = 3.20, 95% confidence interval [CI]: 1.27 to 8.09), and sudden death (age-adjusted OR = 5.73, 95% CI: 1.26 to 26.1). The multivariate OR after adjusting for a range of potential confounding variables was 1.94 (95% CI: 0.70-5.41) for fatal CHD and 4.46 (95% CI: 0.92-21.6) for sudden death. No excess risks were found for nonfatal myocardial infarction or angina.These data suggest an association between anxiety and fatal coronary heart disease, in particular, sudden cardiac death.
Journal of Women's Health
Authors: Linda M. G. Katz
Journal: JAMA (1994)

When asked if women's health is just a fad, Bernadine Healy, MD, former director of the National Institutes of Health, answered, "Women certainly aren't a fad! How could women's health be a fad?"<sup>1</sup>In fact, the Women's Health Initiative launched under Dr Healy's leadership may be the most ambitious clinical research study yet conducted. Obviously, women's health is a legitimate field, but one that is evolving and working to define itself. The<i>Journal of Women's Health</i>can be viewed as a chronicle of the ongoing maturation of an academic discipline. It is of interest for this reason and for its high-quality content. The journal is the official publication of the Society for the Advancement of Women's Health Research, which was established to respond to concerns about the exclusion of women from research studies. The<i>Journal of Women's Health</i>, published since 1992, is an "umbrella" publication, rather than one narrowly
Cholesterol Reduction, Heart Disease, and Mortality
Authors: Charles M. Grossman
Journal: Annals of Internal Medicine (1997)

Letters15 April 1997Cholesterol Reduction, Heart Disease, and MortalityCharles M. Grossman, MDCharles M. Grossman, MDPortland, OR 97205Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-8-199704150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Gaziano and colleagues [1] recently presented yet another study on cholesterol reduction. The authors stated that “there is little doubt that elevated cholesterol levels increase the risk for coronary heart disease.” This statement is made on the basis of results from the consensus conference of 1985 [2], in which the statistically significant difference in rate of myocardial infarction in treated patients compared with control patients was evaluated. Little emphasis was placed on death in that study, although death is clearly the best end point.Are these small numbers clinically important? The authors state that “although most randomized ...References1. Gaziano JM, Hebert PR, Hennekens CH. Cholesterol reduction: weighing the benefits and risks. Ann Intern Med. 1996; 124:914-8. Google Scholar2. Lowering blood cholesterol to prevent heart disease: consensus conference. JAMA. 1985; 253:2080-6. Google Scholar3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival trial (4S). Scandinavian Simvastatin Survival Study Group. Lancet. 1994; 344:1383-9. Google Scholar4. Stehbens WE. Validity of the 4S simvastatin trial [Letter]. Lancet. 1995; 345:264. Google Scholar Author, Article, and Disclosure InformationAuthors: Charles M. Grossman, MDAffiliations: Portland, OR 97205 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 April 1997Volume 126, Issue 8Page: 661KeywordsAnginaCholesterolClinical trial reportingDeath ratesDrugsInfarctionLongitudinal studiesMortalityMyocardial infarctionPenicillin ePublished: 15 August 2000 Issue Published: 15 April 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Unusual Liver Configuration Secondary to Radiation Therapy in Childhood
Authors: KATHERINE D. TOBIN, RICHARD C. ROSENBAUM
Journal: Clinical Nuclear Medicine (1988)

Radiotherapy is frequently used for the treatment of pediatric abdominal tumors. If the liver is incidentally included in the treatment port, the irradiated segments may become small and fibrotic, whereas the unirradiated segments are hypertrophic. A 35-year-old woman who had a right adrenalectomy for neuroblastoma at the age of 1 year is presented. Her treatment included radiation of the tumor bed. The exact radiation port and dosage are unknown. The patient had findings suggestive of acute cholecystitis. Hepatobiliary imaging was performed, and although biliary function was normal, there was an unusual mass-like configuration of the left lobe of the liver that accumulated both Tc-99m DISIDA and sulfur colloid. An abdominal CT showed this mass to be hypertrophy of the left lobe of the liver associated with atrophic changes of the right-sided abdominal organs and musculature in the region of the previously irradiated right adrenal bed.
Litigating reproductive and developmental health in the aftermath of UAW versus Johnson Controls.
Authors: C A Clauss, M Berzon, J Bertin
Journal: Environmental Health Perspectives (1993)

In a major decision handed down last term (International Union [UAW] versus Johnson Controls, Inc.), the Supreme Court ruled that employment practices excluding fertile or pregnant women from the workplace because of alleged concerns for fetal health constitute illegal sex discrimination. We analyze the three opinions in the case and explain why the decision was an essential first step to promoting reproductive and developmental health in the workplace. Continued progress toward eliminating or reducing reproductive occupational risks will require comprehensive legal strategies involving private lawsuits, governmental regulation and enforcement actions, and new legislation designed to preserve the existing rights of workers and to obtain new and additional protections. Finally, we caution that, in designing such strategies, it will be important to avoid solutions that either shift responsibility for reproductive health to workers, rather than to employers, or that undermine other important legal rights.
Abstract 3041: Differential expression of microRNAs between sporadic and hereditary nonmedullary thyroid cancer
Authors: Yin Xiong, Electron Kebebew
Journal: Cancer Research (2010)

Abstract Background: MicroRNAs (miRNAs) are small noncoding RNAs, which regulate gene expression and play a significant role in many biological processes, including tumorigenesis. Approximately 5% of all non-medullary thyroid cancers are hereditary and may have more aggressive tumor biology than sporadic cases. The susceptibility gene for hereditary non-medullary thyroid cancer has not been identified. We hypothesized that miRNA expression profile between sporadic and hereditary non-medullary thyroid cancer are different and could help identify candidate suspceptibility genes. Methods: Twenty nine tumor tissue samples were analyzed using miRNA microarrays for 1190 miRNAs with genotyping for common somatic mutations (BRAF V600E, NRAS, KRAS, RET/PTC1, RET/PTC3) present in non-medullary thyroid cancer. The samples were matched for age, gender and stage of cancer. Differences in miRNA expression profile were validated by quantitative RT-PCR and correlated with clinicopathologic data. Results: We found 5 miRNAs significantly differentially expressed between sporadic and hereditary non-medullary thyroid cancer cases; two miRNAs were upregulated and three miRNAs were downregulated in hereditary non-medullary thyroid cancer. Two miRNAs were validated by quantitative RT-PCR; miR-20a (p=0.025) and miR-886-3p (p=0.028) were upregulated in hereditary non-medullary thyroid cancer samples. Higher expression level of miR-886-3p was significantly associated with higher TNM stage (p&amp;lt;0.05). There was no significant difference in somatic mutation rates between sporadic and hereditary cases (9 BRAF V600E, 1 RET/PTC1), and there was no significant difference in miR-20a and miR-886-3p expression by mutation status. Conclusions: To our knowledge, this is the first study to show different expression profile of miRNAs between sporadic and hereditary cancer using non-medullary thyroid cancer as a model. These differences in miRNAs may have an important role in tumor cell biology and clinical manifestation of non-medullary thyroid cancer in sporadic versus hereditary cases. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3041.
Sizing Up Scoliosis
Authors: Paul D. Sponseller
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hiroshima and the Art of Iri Maruki and Toshi Maruki
Authors: John Junkerman
Journal: JAMA (1987)

THE FIRES were still burning throughout Hiroshima when Iri Maruki arrived in the devastated city, his birthplace, three days after the atomic bomb was dropped on Aug 6, 1945. Concerned about the fate of his family, Iri had taken the first train from Tokyo after reading newspaper reports of the powerful new bomb. He did not know what he would find at the end of his long journey. "It was the dead of night when we finally reached Hiroshima Station," Iri later recalled. "After the train stopped, I could not bring myself to move for a long time. Finally I got up and staggered, like a sleepwalker, off the train. There was no station building, no sign of life. Though it was dark, I could see all the way to Hiroshima Bay and the islands of the Inland Sea." In a state of shock, Iri made his way
Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy
Authors: G.I STABLES, M.R. STRINGERy, D.J ROBINSON, D.V ASH
Journal: British Journal of Dermatology (1997)

Large patches of Bowen's disease (intraepidermal carcinoma in situ) can be difficult to treat by conventional methods. Photodynamic therapy (PDT) uses the combination of a photosensitizer, which preferentially accumulates in malignant cells, and photoactivation by visible light to kill the malignant cells. 5-aminolaevulinic acid (ALA) PDT uses excess exogenous ALA, which produces, via the haem synthesis pathway, a build up of the photosensitizer protoporphyrin IX. We describe the use of topical ALA PDT to treat three patients with three especially large patches of Bowen's disease. Following two treatments all three lesions achieved a complete clinical and histological response with a good cosmetic result. ALA PDT is a simple, effective and well tolerated treatment for large patches of Bowen's disease.
Critical role for Syk in responses to vascular injury
Authors: Patrick Andre, Toshifumi Morooka, Derek Sim, Keith Abe, Clifford Lowell, Nisha Nanda, Suzanne Delaney, Gail Siu, Yibing Yan, Stan Hollenbach, Anjali Pandey, Huiyun Gao, Yunmei Wang, Kohsuke Nakajima, Sahil A. Parikh, Can Shi, David Phillips, Whyte Owen, Uma Sinha, Daniel I. Simon
Journal: Blood (2011)
Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells
Authors: Angela Papageorgiou, Laura Lashinger, Randall Millikan, H. Barton Grossman, William Benedict, Colin P. N. Dinney, David J. McConkey
Journal: Cancer Research (2004)

Abstract Immunomodulators such as Bacillus Calmette-Guerin and interferon are clinically active in transitional cell carcinoma of the bladder, but their mechanisms of action remain unclear. Here we investigated the effects of IFNα on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and apoptosis in a panel of 20 human bladder cancer cell lines. Six (30%) displayed significant DNA fragmentation in response to increasing concentrations of IFNα (10–100,000 units/mL). In these lines IFNα induced early activation of caspase-8, and DNA fragmentation was blocked by a caspase-8-selective inhibitor (IETDfmk), consistent with the involvement of death receptor(s) in cell death. IFNα stimulated marked increases in TRAIL mRNA and protein in the majority of IFN-sensitive and IFN-resistant cell lines. A blocking anti-TRAIL antibody significantly inhibited IFN-induced DNA fragmentation in four of six IFN-sensitive cell lines, confirming that TRAIL played a direct role in cell death. Bortezomib (PS-341, Velcade), a potent TRAIL-sensitizing agent, increased sensitivity to IFNα in two of the IFN-resistant cell lines that produced large amounts of TRAIL in response to IFN treatment. Our data show that IFN-induced apoptosis in bladder cancer cells frequently involves autocrine TRAIL production. Combination therapy strategies aimed at overcoming TRAIL resistance may be very effective in restoring IFN sensitivity in a subset of human bladder tumors.
Effects of 20 days of bed rest on the viscoelastic properties of tendon structures in lower limb muscles
Authors: K Kubo, H Akima, J Ushiyama, I Tabata, H Fukuoka, H Kanehisa, T Fukunaga
Journal: British Journal of Sports Medicine (2004)

Objectives: The purpose of this study was to investigate the effects of 20 days’ bed rest on the viscoelastic properties of human tendon structures in knee extensor and plantar flexor muscles in vivo. Methods: Eight healthy men (age: 24±4 years, height: 172±9 m, body mass: 69±13 kg) carried out a 6° head-down bed rest for 20 days. Before and after bed rest, elongation (L) of the tendon and aponeurosis of vastus lateralis (VL) and medial gastrocnemius muscles (MG) during isometric knee extension and plantar flexion, respectively, were determined using real-time ultrasonic apparatus, while the subjects performed ramp isometric contraction up to the voluntary maximum, followed by ramp relaxation. The relationship between estimated muscle force (Fm) and tendon elongation (L) was fitted to a linear regression, the slope of which was defined as stiffness. The hysteresis was calculated as the ratio of the area within the Fm-L loop to the area beneath the load portion of the curve. Results: L values above 100 N were significantly greater after bed rest for VL, while there were no significant differences in L values between before and after for MG. The stiffness decreased after bed rest for VL (70.3±27.4 v 50.1±24.8 N/mm, before and after bed rest, respectively; p = 0.003) and MG (29.4±7.5 v 25.6±7.8 N/mm, before and after bed rest, respectively; p = 0.054). In addition, hysteresis increased after bed rest for VL (16.5±7.1% v 28.2±12.9%, before and after bed rest, respectively; p = 0.017), but not for MG (17.4±4.4% v 17.7±6.1%, before and after bed rest, respectively; p = 0.925). Conclusions: These results suggested that bed rest decreased the stiffness of human tendon structures and increased their hysteresis, and that these changes were found in knee extensors, but not the plantar flexors.
Nkx2-5 Represses <i>Gata1</i> Gene Expression and Modulates the Cellular Fate of Cardiac Progenitors During Embryogenesis
Authors: Arianna Caprioli, Naoko Koyano-Nakagawa, Michelina Iacovino, Xiaozhong Shi, Anwarul Ferdous, Richard P. Harvey, Eric N. Olson, Michael Kyba, Daniel J. Garry
Journal: Circulation (2011)

Recent studies suggest that the hematopoietic and cardiac lineages have close ontogenic origins, and that an early mesodermal cell population has the potential to differentiate into both lineages. Studies also suggest that specification of these lineages is inversely regulated. However, the transcriptional networks that govern the cell fate specification of these progenitors are incompletely defined.Here, we show that Nkx2-5 regulates the hematopoietic/erythroid fate of the mesoderm precursors early during cardiac morphogenesis. Using transgenic technologies to isolate Nkx2-5 expressing cells, we observed an induction of the erythroid molecular program, including Gata1, in the Nkx2-5-null embryos. We further observed that overexpression of Nkx2-5 with an Nkx2-5-inducible embryonic stem cell system significantly repressed Gata1 gene expression and suppressed the hematopoietic/erythroid potential, but not the endothelial potential, of the embryonic stem cells. This suppression was cell-autonomous, and was partially rescued by overexpressing Gata1. In addition, we demonstrated that Nkx2-5 binds to the Gata1 gene enhancer and represses the transcriptional activity of the Gata1 gene.Our results demonstrate that the hematopoietic/erythroid cell fate is suppressed via Nkx2-5 during mesodermal fate determination, and that the Gata1 gene is one of the targets that are suppressed by Nkx2-5.
NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse
Authors: Gilles Kauffenstein, Annick Drouin, Nathalie Thorin-Trescases, Hélène Bachelard, Bernard Robaye, Pedro D'Orléans-Juste, François Marceau, Éric Thorin, Jean Sévigny
Journal: Cardiovascular Research (2009)

Extracellular nucleotides are vasoactive molecules. The concentrations of these molecules are regulated by ectonucleotidases. In this study, we investigated the role of the blood vessel ectonucleotidase NTPDase1, in the vasoconstrictor effect of nucleotides using Entpd1−/− mice. Immunofluorescence, enzyme histochemistry, and HPLC analysis were used to evaluate both NTPDase expression and activity in arteries and isolated vascular smooth muscle cells (VSMCs). Vascular reactivity was evaluated in vitro and mean arterial blood pressure was recorded in anesthetized mice after nucleotide i.v. infusion. Expression of nucleotide receptors in VSMCs was determined by RT–PCR. Entpd1−/− mice displayed a dramatic deficit of nucleotidase activity in blood vessel wall in situ and in VSMCs in comparison to control mice. In aortic rings from Entpd1−/− mice, UDP and UTP induced a potent and long-lasting constriction contrasting with the weak response obtained in wild-type rings. This constriction occurred through activation of P2Y6 receptor and was independent of other uracil nucleotide-responding receptors (P2Y2 and P2Y4). UDP infusion in vivo increased blood pressure and this effect was potentiated in Entpd1−/− mice. In addition, pressurized mesenteric arteries from Entpd1−/− mice displayed an enhanced myogenic response, consistent with higher local concentrations of endogenously released nucleotides. This effect was inhibited by the P2 receptor antagonist RB-2. NTPDase1 is the major enzyme regulating nucleotide metabolism at the surface of VSMCs and thus contributes to the local regulation of vascular tone by nucleotides.